Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma

Interventions

DRUG: omalizumab at a dose of 0.016mg/kg/IU/mL
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]